Compounds for the treatment of myotonic dystrophy

The present invention relates to a compound of formula (I), provided that this compound is not caffeine, for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising the compound of formula (I) as defined herein. The present inventio...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	LÓPEZ GONZÁLEZ, ALEJANDRO, CASTELLS BOLIART, JOSEP, ARTERO ALLEPUZ, RUBEN, KONIECZNY, PIOTR, LLAMUSI TROISI, BEATRIZ, PASCUAL GILABERT, MARTA, TEIXIDÓ CLOSA, JORDI, BORRELL BILBAO, JOSÉ IGNACIO, BARGIELA SCHÉNBRUNN, ARIADNA, ESTRADA TEJEDOR, ROGER
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to a compound of formula (I), provided that this compound is not caffeine, for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising the compound of formula (I) as defined herein. The present invention further relates to new compounds which are dimers of compounds of formula (I).